Advertisement

Clinical Drug Investigation

, Volume 36, Issue 12, pp 985–992 | Cite as

A Randomized, Double-blind, Active-Controlled, Multi-center Study of Ilaprazole in the Treatment of Reflux Esophagitis

  • Yan Xue
  • Xianghong Qin
  • Liya ZhouEmail author
  • Sanren Lin
  • Ling Wang
  • Haitang Hu
  • Jielai Xia
Original Research Article

Abstract

Background and Objective

Proton pump inhibitors (PPIs) are the main drugs for the treatment of reflux esophagitis. Previous studies have indicated ilaprazole to be safer and more effective in treating duodenal ulcers as compared with omeprazole. Being a novel PPI, ilaprazole may be used in the treatment of reflux esophagitis. The purpose of this study was to evaluate the safety and efficacy of ilaprazole tablets in the treatment of reflux esophagitis.

Methods

This study used a randomized, double-blind, multi-center, active-comparison design. The patients were randomly divided into an ilaprazole group (10 mg once daily and 15 mg once daily) and an esomeprazole group (40 mg once daily). Both the groups were treated for 8 weeks. Heartburn and reflux symptoms prior to treatment, and 4 and 8 weeks after the treatment were assessed. Gastroscopy was performed after 4 and 8 weeks. The healing rate after 4 weeks treatment was compared. If esophagitis was healed at the end of 4 weeks, patients did not undergo gastroscopy at the end of 8 weeks.

Results

Three hundred and twenty-five patients were enrolled in this study. The 4-week full analysis set (per-protocol set) healing rates in the esomeprazole 40-mg group, the ilaprazole 10-mg group, and the ilaprazole 15-mg group were: 71.43 % (78.89 %), 81.31 % (86.73 %), and 71.70 % (81.40 %), respectively, p = 0.1595 (0.4122); the 8-week healing rates were 84.76 % (93.33 %), 88.79 % (94.90 %), and 85.85 % (97.67 %), respectively, p = 0.6689 (0.4049). Drug-related adverse events rate were 10.48 %, 14.02 %, and 15.09 %, respectively, in the three groups (p = 0.6114).

Conclusion

The efficacy and safety of ilaprazole (10 mg/day, 15 mg/day) in treating reflux esophagitis was similar to esomeprazole (40 mg/day). Ilaprazole (10 mg/day) has a smaller dosage, hence it should be considered more in clinical uses.

Trial registration: ClinicalTrials.gov NCT01107938.

Keywords

Proton Pump Inhibitor Esomeprazole Reflux Esophagitis Proton Pump Inhibitor Treatment Disappearance Time 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

The authors wish to acknowledge the Department of Gastroenterology, Peking Union Medical College Hospital; Department of Gastroenterology, The General Hospital of the People’s Liberation Army; Department of Gastroenterology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine; Department of Gastroenterology, Changhai Hospital, Shanghai; Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University; Department of Gastroenterology, Wuhan Union Hospital; Department of Gastroenterology, Renmin Hospital of Wuhan University; Department of Gastroenterology, Guangzhou First People’s Hospital.

Compliance with Ethical Standards

Funding

The study was sponsored by Livzon Pharmaceutical Group Inc., China.

Funding

The study was sponsored by Livzon Pharmaceutical Group Inc., China.

Conflict of interest

Xianghong Qin is an employee of Livzon Pharmaceutical Group Inc. Yan Xue, Liya Zhou, Sanren Lin, Ling Wang, Haitang Hu, and Jielai Xia declare no conflicts of interest that affect the results of the study.

Ethical approval

This study was approved by the Ethics Committee of the Health Center of Peking University.

Informed consent

All study participants provided written informed consent before being included in the study.

References

  1. 1.
    Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005;54:710–7.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Jung HK. Epidemiology of gastroesophageal reflux disease in Asia: a systematic review. J Neurogastroenterol Motil. 2011;17:14–27.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013;108:308–28.CrossRefPubMedGoogle Scholar
  4. 4.
    Ho KY, Kuan A, Zano F, et al. Randomized, parallel, double-blinded comparison of the ulcer-healing effects of ilaprazole and omeprazole in the treatment of gastric and duodnal ulcers. J Gastroenterol. 2009;44:697–707.CrossRefPubMedGoogle Scholar
  5. 5.
    Wang L, Zhou L, Lin S, et al. A new PPI, ilaprazole compared with omeprazole in the treatment of duodenal ulcer: a randomized double-blind multicenter trial. J Clin Gastoenterol. 2011;45:322–9.CrossRefGoogle Scholar
  6. 6.
    Wang L, Zhou L, Hu H, et al. Ilaprazole for the treatment of duodenal ulcer: a randomized, double-blinded and controlled phase III trial. Curr Med Res Opin. 2012;28:101–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Armstrong D, Bennett JR, Blum AL, et al. The endoscopic assessment of esophagitis: a progress report on observer assesment. Gastroenterology. 1996;111(1):85–92.CrossRefPubMedGoogle Scholar
  8. 8.
    Moayyedi P, Talley NJ. Gastro-oesophageal reflux disease. Lancet. 2006;367:2086–100.CrossRefPubMedGoogle Scholar
  9. 9.
    Vakil N, vanZenten SV, Kahrilas P, Global Consensus Group, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900–20.CrossRefPubMedGoogle Scholar
  10. 10.
    Li Y, Zhang W, Guo D. Pharmacokinetics of the new proton pump inhibitor ilaprazole in Chines healthy subjects in relation to CYP3A5 and CYP2C19 genotypes. Clin Chim Acta. 2008;391(1/2):60–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Du YQ, Guo WY, Zou DW, et al. Acid inhibition effect of ilprazlole on Helicobacter pylori-negative healthy volunteers: an open randomized cross-over study. J Dig Dis. 2012;13:113–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Cho H, Choi MK, Cho DY, et al. Effect of CYP2C19 genetic polymorphism on pharmacokinetics and pharmacodynamics of a new proton pump inhibitor, ilaprazole. J Clin Pharmacol. 2012;52:976–84.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Yan Xue
    • 1
  • Xianghong Qin
    • 2
  • Liya Zhou
    • 1
    Email author
  • Sanren Lin
    • 1
  • Ling Wang
    • 3
  • Haitang Hu
    • 2
  • Jielai Xia
    • 3
  1. 1.Department of GastroenterologyPeking University Third Hospital BeijingBeijingChina
  2. 2.Livzon Pharmacertical Group Inc.ZhuhaiChina
  3. 3.The Fourth Military Medical UniversityXi’anChina

Personalised recommendations